Approval · Notice of Compliance 33087 · 2024
DIPENTUM: Notice of Compliance 33087
Issued April 19, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33087
- Date
- April 19, 2024
- Company
- Atnahs Pharma Uk LimitedBasildon, Essex, United Kingdom
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update labels to align with plain language labelling regulations, and conversion of the Product Monograph to the Master Template.
- Canadian reference product
- CRESTOR (Astrazeneca Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DIPENTUM | Not yet assigned | — |
Medicinal ingredients
- OLSALAZINE SODIUM 250 MG per CAP